144 related articles for article (PubMed ID: 37475819)
1. Evaluation of Serum Fructosamine as Diagnostic Marker of Postoperative Recurrence in the Patients with Breast Cancer.
Zhao Y; Xie X; Xie J; Zhang L; Li B; Liu J; Jiang H
Biomed Res Int; 2023; 2023():6435776. PubMed ID: 37475819
[TBL] [Abstract][Full Text] [Related]
2. Changes of Tumor Markers in Patients with Breast Cancer during Postoperative Adjuvant Chemotherapy.
Zhang Y; Zhao J; Wang Y; Cai W; Zhang X; Li K; Liu W; Zhao Y; Kang H
Dis Markers; 2022; 2022():7739777. PubMed ID: 35634442
[TBL] [Abstract][Full Text] [Related]
3. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer.
Lian M; Zhang C; Zhang D; Chen P; Yang H; Yang Y; Chen S; Hong G
J Clin Lab Anal; 2019 Jun; 33(5):e22875. PubMed ID: 30843272
[TBL] [Abstract][Full Text] [Related]
4. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
5. Postoperative recurrence analysis of breast cancer patients based on clinical serum markers using discriminant methods.
Li L; Gao Q; Xu G; Shi B; Ma X; Liu H; Li Q; Tian T; Tang J; Niu H
Cancer Biomark; 2017 Jul; 19(4):403-409. PubMed ID: 28582844
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of preoperative serum neutrophil-to-lymphocyte ratio and tumor markers for early breast cancer patients: A retrospective study.
Fan S; Xie X; Shen Y; Wang W; Gu X; Yao Z
Medicine (Baltimore); 2022 Aug; 101(32):e30011. PubMed ID: 35960055
[TBL] [Abstract][Full Text] [Related]
7. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause.
Wang XF; Wu YH; Wang MS; Wang YS
Asian Pac J Cancer Prev; 2014; 15(1):363-8. PubMed ID: 24528057
[TBL] [Abstract][Full Text] [Related]
8. Strategies for five tumour markers in the screening and diagnosis of female breast cancer.
Luo J; Xiao J; Yang Y; Chen G; Hu D; Zeng J
Front Oncol; 2022; 12():1055855. PubMed ID: 36755860
[TBL] [Abstract][Full Text] [Related]
9. Different Levels of CEA, CA153 and CA125 in Milk and Benign and Malignant Nipple Discharge.
Zhao S; Mei Y; Wang J; Zhang K; Ma R
PLoS One; 2016; 11(6):e0157639. PubMed ID: 27327081
[TBL] [Abstract][Full Text] [Related]
10. [Establishment and validation of a predictive nomogram model for advanced gastric cancer with perineural invasion].
Liu SH; Hou XY; Zhang XX; Liu GW; Xin FJ; Wang JG; Zhang DL; Wang DS; Lu Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Nov; 23(11):1059-1066. PubMed ID: 33212554
[No Abstract] [Full Text] [Related]
11. [The value of tumor markers CA 15-3 and CEA in breast cancer].
Buck I; Lindner C; Böge K; Kitschke HJ
Arch Gynecol Obstet; 1989; 245(1-4):674-7. PubMed ID: 2802753
[TBL] [Abstract][Full Text] [Related]
12. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
13. Serum carcinoembryonic antigen to predict recurrence in the follow-up of patients with colorectal cancer.
Ramphal W; Boeding JRE; van Iwaarden M; Schreinemakers JMJ; Rutten HJT; Crolla RMPH; Gobardhan PD
Int J Biol Markers; 2019 Mar; 34(1):60-68. PubMed ID: 30852955
[TBL] [Abstract][Full Text] [Related]
14. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
[TBL] [Abstract][Full Text] [Related]
15. Combination of Neutrophil-to-Lymphocyte Ratio and Red Cell Distribution Width With Serum Tumor Markers for the Differential Diagnosis of Breast Cancer and its Association With Pathological Features and Molecular Types.
Zou H; Liu SH; Yang R; Wu XJ; Cao YP; Huang HF
Clin Breast Cancer; 2022 Jun; 22(4):e526-e535. PubMed ID: 34963613
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of tumour marker velocity of cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) in breast cancer surveillance.
Hing JX; Mok CW; Tan PT; Sudhakar SS; Seah CM; Lee WP; Tan SM
Breast; 2020 Aug; 52():95-101. PubMed ID: 32485607
[TBL] [Abstract][Full Text] [Related]
18. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
